立体定向消融放疗联合内分泌治疗替代手术治疗低危乳腺癌的前瞻性II期试验
19例活检者中pCR率为53%(95%CI 30-73%),12例未手术者3年PFS为92%(95%CI 54-99%),无乳腺癌复发。
要点
- SABR联合内分泌治疗在选择性低危HR+乳腺癌中pCR率达53%(95%CI 30-73%)。
- 12例免手术患者3年PFS为92%(95%CI 54-99%),无乳腺癌复发。
- 决策后悔和乳腺特异性患者报告结局保持稳定。
核心结论
- 根治性SABR联合内分泌治疗在选择性低危HR+乳腺癌中取得较高pCR率和令人鼓舞的肿瘤控制。
研究设计与样本
- 患者接受3个月内分泌治疗后行5次SABR,SABR后6-12个月行真空辅助影像引导核心活检。
- pCR者免手术,共同主要终点为pCR率和3年PFS率。
主要发现
- 19例SABR后活检患者中pCR为10/19(53%,95%CI 30-73%),7例(37%)为近完全缓解。
- 12例未手术患者中位随访44.9个月,3年PFS为92%(95%CI 54-99%),无乳腺癌复发,1例非乳腺癌相关死亡。
- 纵向患者报告结局中决策后悔和乳腺特异性结局保持稳定。
关键数值与推荐
- pCR定义为SABR后6-12个月肿瘤床活检病理完全缓解,pCR者免于手术。
- 采用贝叶斯框架通过后验概率评估无效性,以评估有临床意义的pCR率。
临床怎么用
- 对于经仔细选择的 favorable HR+早期乳腺癌患者,SABR联合内分泌治疗可作为非手术根治策略的探索方向。
- SABR后6-12个月肿瘤床活检可用于筛选pCR患者免于手术。
局限性
- 单臂II期设计,需进一步评估放疗为基础根治治疗及免手术策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early-stage, hormone receptor positive (HR+) breast cancer has excellent outcomes with lumpectomy, radiotherapy, and endocrine therapy (ET), prompting interest in treatment de-escalation. Advances in stereotactic ablative radiotherapy (SABR) raise the possibility of definitive local therapy without surgery in select patients. We conducted a prospective, phase II trial (NCT02945579) evaluating SABR with ET as a non-operative strategy. MATERIALS AND METHODS: Patients aged ≥ 40 years with cT1N0M0, unicentric, HR+, HER2-negative breast cancer received 3 months of ET followed by SABR in 5 fractions. Vacuum-assisted image-guided core biopsy of the tumor bed was performed 6-12 months after SABR. Patients with pathologic complete response (pCR) omitted surgery. Co-primary endpoints were pCR and 3-year progression-free survival (PFS) rates. Patient-reported outcomes were collected as a secondary endpoint. A Bayesian framework evaluated futility using posterior probabilities to assess a clinically meaningful pCR rate. RESULTS: Twenty patients were enrolled (median age 70.5 years). Nineteen underwent biopsy after SABR. pCR was observed in 10/19 patients (53%, 95% CI 30-73%), and 7 (37%) had near complete response. Among the 12 patients managed without surgery, median follow-up was 44.9 months. Three-year PFS was 92% (95% CI 54-99%), with one non-breast cancer-related death and no breast cancer recurrences. Longitudinal patient-reported outcomes of decisional regret and breast-specific outcomes remained stable. CONCLUSION: Definitive SABR combined with ET achieved substantial pCR rates and encouraging tumor control. These findings support further evaluation of radiotherapy-based definitive treatment and potential surgery omission in carefully selected patients with favorable, HR + breast cancer.
引用
- Shaitelman SF, Krishnamurthy S, Rauch GM, et al. Definitive, stereotactic ablative radiotherapy and endocrine therapy without surgery for select low-risk breast cancers: A prospective, phase II trial. Radiother Oncol. 2026. PMID: 42142534. doi:10.1016/j.radonc.2026.111573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。